Welcome to our dedicated page for Merck & Co. news (Ticker: MRK), a resource for investors and traders seeking the latest updates and insights on Merck & Co. stock.
Merck & Co., Inc. (NYSE: MRK), known as MSD outside the United States and Canada, is a renowned American multinational pharmaceutical company headquartered in Rahway, New Jersey. Originally the American arm of Germany's Merck Group founded in 1668, Merck has established itself as a global leader in pharmaceuticals and vaccines.
Merck's core business is the development and manufacturing of medications and vaccines spanning several therapeutic areas such as cardiometabolic diseases, cancer, and infections. The company's immuno-oncology platform, particularly strong in cancer treatment, is a significant revenue driver. The firm’s oncology portfolio includes groundbreaking immunotherapies like KEYTRUDA, designed to treat melanoma and other cancers. KEYTRUDA, in combination with other therapies, has shown promising results in reducing cancer recurrence and improving survival rates.
Merck also boasts a robust vaccine business, offering vaccines for pediatric diseases and human papillomavirus (HPV). Their commitment to public health extends to Merck for Mothers, an initiative aimed at improving maternal health globally. In 2024, Merck surpassed its goal early by reaching over 30 million women with programs promoting safe, high-quality maternal care.
The company's animal health division is another sector of its diverse operations, providing solutions to improve animal health and productivity.
From a geographical perspective, nearly half of Merck's sales are generated in the United States. Financially, Merck maintains a solid position with ongoing investments in research and development to fuel innovation. The company is actively engaged in numerous partnerships and collaborative research initiatives to accelerate the development of new therapies.
Merck’s mission is rooted in scientific excellence and an unwavering commitment to improving lives. The company continues to invest in leading-edge research, with over 2,250 ongoing clinical trials, including more than 1,600 trials evaluating combination regimens. This dedication underpins Merck's strategy to address complex health challenges and advance global health.
Merck (NYSE: MRK) has declared a quarterly dividend of
Merck's KEYTRUDA has been approved by Japan's PMDA as a first-line treatment for advanced esophageal cancer in combination with chemotherapy (5-FU and cisplatin). This marks KEYTRUDA's 16th indication in Japan. The approval is based on the Phase 3 KEYNOTE-590 trial, which showed a 27% reduction in death risk and a 35% reduction in disease progression compared to standard chemotherapy. Esophageal cancer poses a significant health burden in Japan, with over 26,000 new cases annually. Merck continues to expand KEYTRUDA's applications in various gastrointestinal cancers.
Merck (NYSE: MRK) and AstraZeneca announced the acceptance of a supplemental New Drug Application for LYNPARZA, targeting BRCA mutations in early-stage HER2-negative breast cancer. The FDA granted priority review, with a target action date in Q1 2022. The application was based on the Phase 3 OlympiA trial, showing a 42% reduction in the risk of invasive breast cancer recurrence. LYNPARZA is already approved for several cancer indications, and its safety profile aligns with previous trials, with common adverse events including nausea and fatigue.
Merck (NYSE: MRK) and Eisai announced the European Commission's approval of KEYTRUDA and LENVIMA for treating advanced or recurrent endometrial carcinoma in adults. This is the first combination of an immunotherapy with a tyrosine kinase inhibitor approved in Europe for patients who have seen disease progression after platinum-based therapies and are not surgical candidates.
The decision is based on the pivotal Phase 3 KEYNOTE-775/Study 309, showing a 38% reduction in death risk and a 44% reduction in disease progression risk compared to chemotherapy.
Merck (NYSE: MRK) and Eisai announced that the European Commission has approved the combination therapy of KEYTRUDA and LENVIMA for treating advanced renal cell carcinoma (RCC). This decision follows results from the CLEAR/KEYNOTE-581 trial, showing that this combination reduced the risk of disease progression or death by 61% compared to sunitinib, with a median progression-free survival of 23.9 months. The combination also showed an overall survival benefit and a higher objective response rate, providing new hope for advanced RCC patients in Europe.
Merck (NYSE: MRK) and Ridgeback Biotherapeutics have released data from the MOVe-OUT study of molnupiravir, an oral antiviral for COVID-19. The study, involving 1,433 participants, showed a reduction in hospitalization or death rates from 9.7% in the placebo group to 6.8% in the treatment group, achieving a 30% relative risk reduction. The FDA is reviewing Merck's Emergency Use Authorization application, with discussions scheduled for Nov. 30. Previously, an interim analysis had indicated even greater efficacy, reducing risks by 48%.
Merck (NYSE: MRK) will have Frank Clyburn, EVP and Human Health President, participate in the 4th Annual Evercore ISI HealthCONx Conference. The virtual event is set for December 1, 2021, at 10:30 a.m. ET. Investors, analysts, and the general public can access a live webcast of the presentations at Merck's investor relations website. Merck, a leading biopharmaceutical company with a legacy of over 130 years, focuses on developing innovative medicines and vaccines to enhance health outcomes globally.
Organon (NYSE: OGN) announced that CEO Kevin Ali and CFO Matthew Walsh will participate in a fireside chat at the Evercore ISI 4th Annual HealthCONx Conference on December 1, 2021, at 1:50 p.m. ET. Investors, analysts, and the public can access a live video webcast at this link. Organon focuses on women's health and has over 60 products across various therapeutic areas, serving over 140 markets globally and employing approximately 9,000 people.
Merck (NYSE: MRK) has successfully completed the acquisition of Acceleron Pharma Inc. (NASDAQ: XLRN), enhancing its cardiovascular portfolio. CEO Rob Davis highlighted this acquisition as a strategic move aimed at expanding market opportunities and addressing critical health needs. Acceleron’s lead candidate, sotatercept, targets pulmonary arterial hypertension and is currently in Phase 3 trials. This acquisition aims to strengthen Merck’s pipeline and further its longstanding commitment to cardiovascular health.
Merck (NYSE: MRK) has successfully completed its cash tender offer for all outstanding shares of Acceleron Pharma Inc. (NASDAQ: XLRN) at a price of $180 per share. By the offer's expiration on November 19, 2021, approximately 63.3% of Acceleron’s shares were tendered. Following the merger, Acceleron will become a wholly owned subsidiary of Merck, and its stock will cease trading on Nasdaq. The acquisition aims to enhance Merck's portfolio and market presence in the biopharmaceutical space.
FAQ
What is the current stock price of Merck & Co. (MRK)?
What is the market cap of Merck & Co. (MRK)?
What are the main therapeutic areas Merck focuses on?
What is Merck for Mothers?
What are some of Merck’s key products in oncology?
How significant is Merck’s vaccine business?
Where is Merck headquartered?
What percentage of Merck’s sales comes from the United States?
What is Merck's approach to research and development?
What recent achievements has Merck announced?
Does Merck collaborate with other companies for research?
What is the historical origin of Merck & Co., Inc.?
